nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

25.05.2017 | Guidelines

Guideline for PET/CT imaging of neuroendocrine neoplasms with ⁶⁸Ga-DOTA-conjugated somatostatin receptor targeting peptides and ¹⁸F–DOPA

verfasst von: Murat Fani Bozkurt, Irene Virgolini, Sona Balogova, Mohsen Beheshti, Domenico Rubello, Clemens Decristoforo, Valentina Ambrosini, Andreas Kjaer, Roberto Delgado-Bolton, Jolanta Kunikowska, Wim J. G. Oyen, Arturo Chiti, Francesco Giammarile, Stefano Fanti

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 9/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose & Methods

Neuroendocrine neoplasms are a heterogenous group of tumours, for which nuclear medicine plays an important role in the diagnostic work-up as well as in the targeted therapeutic options. This guideline is aimed to assist nuclear medicine physicians in recommending, performing, reporting and interpreting the results of somatostatin receptor (SSTR) PET/CT imaging using ⁶⁸Ga-DOTA-conjugated peptides, as well as ¹⁸F-DOPA imaging for various neuroendocrine neoplasms.

Results & Conclusion

The previous procedural guideline by EANM regarding the use PET/CT tumour imaging with ⁶⁸Ga-conjugated peptides has been revised and updated with the relevant and recent literature in the field with contribution of distinguished experts.

Bombardieri E, Maccauro M, De Deckere E, Savelli G, Chiti A. Nuclear medicine imaging of neuroendocrine tumours. Ann Oncol. 2001;12(Suppl 2):S51–61.CrossRefPubMed

Olsen JO, Pozderac RV, Hinkle G, Hill T, O’Dorisio TM, Schirmer WJ, et al. Somatostatin receptor imaging of neuroendocrine tumors with indium-111 pentetreotide (Octreoscan). Semin Nucl Med. 1995;25:251–61.CrossRefPubMed

Briganti V, Sestini R, Orlando C, Bernini G, La Cava G, Tamburini A, et al. Imaging of somatostatin receptors by indium-111-pentetreotide correlates with quantitative determination of somatostatin receptor type 2 gene expression in neuroblastomatumors. Clin Cancer Res. 1997;3:2385–91.PubMed

Chiti A, Briganti V, Fanti S, Monetti N, Masi R, Bombardieri E. Results and potential of somatostatin receptor imaging in gastroenteropancreatic tract tumours. Q J Nucl Med. 2000;44:42–9.PubMed

Chiti A, Fanti S, Savelli G, Romeo A, Bellanova B, Rodari M, et al. Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours. Eur J Nucl Med. 1998;25:1396–403.CrossRefPubMed

Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993;20:716–31.CrossRefPubMed

Seregni E, Chiti A, Bombardieri E. Radionuclide imaging of neuroendocrine tumours: biological basis and diagnostic results. Eur J Nucl Med. 1998;25:639–58.CrossRefPubMed

Jamar F, Fiasse R, Leners N, Pauwels S. Somatostatin receptor imaging with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors: safety, efficacy and impact on patient management. J Nucl Med. 1995;36:542–9.PubMed

Lebtahi R, Cadiot G, Sarda L, Daou D, Faraggi M, Petegnief Y, et al. Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatictumors. J Nucl Med. 1997;38:853–8.PubMed

10.

Kowalski J, Henze M, Schuhmacher J, Maecke HR, Hofmann M, Haberkorn U. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D-Phe1 Tyr3-octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol. 2003;5:42–8.CrossRefPubMed

11.

Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumors: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging. 2003;30:781–93.CrossRefPubMed

12.

Buchmann I, Henze M, Engelbrecht S, Eisenhut M, Runz A, Schäfer M, et al. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2007;34:1617–26.CrossRefPubMed

13.

Hofmann M, Maecke H, Börner R, Weckesser E, Schöffski P, Oei L, et al. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur J Nucl Med. 2001;28:1751–7.CrossRefPubMed

14.

Wild D, Schmitt JS, Ginj M, Mäcke HR, Bernard BF, Krenning E, et al. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging. 2003;30:1338–47.CrossRefPubMed

15.

Campana D, Ambrosini V, Pezzilli R, Fanti S, Labate AM, Santini D, et al. Standardized uptake values of 68Ga-DOTANOC PET: a promising prognostic tool in neuroendocrine tumors. J Nucl Med. 2010;51:353–9.CrossRefPubMed

16.

Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med. 2007;48:508–18.CrossRefPubMed

17.

Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev. 2003;24:389–427.CrossRefPubMed

18.

Putzer D, Kroiss A, Waitz D, Gabriel M, Traub-Weidinger T, Uprimny C, et al. Somatostatin receptor PET in neuroendocrine tumours: (68)Ga-DOTA (0),Tyr (3)-octreotide versus (68)Ga-DOTA (0)-lanreotide. Eur J Nucl Med Mol Imaging. 2013;40:364–72.CrossRefPubMed

19.

Pfeifer A, Knigge U, Mortensen J, Oturai P, Berthelsen AK, Loft A, et al. Clinical PET of neuroendocrine tumors using 64Cu-DOTATATE: first-in-humans study. J Nucl Med. 2012;53:1207–15.CrossRefPubMed

20.

Binderup T, Knigge U, Mellon Mogensen A, Palnaes Hansen C, Kjaer A. Quantitative gene expression of somatostatin receptors and noradrenaline transporter underlying scintigraphic results in patients with neuroendocrine tumors. Neuroendocrinology. 2008;87:223–32.CrossRefPubMed

21.

Wang X, Fani M, Schulz S, Rivier J, Reubi JC, Maecke HR. Comprehensive evaluation of a somatostatin-based radiolabelled antagonist for diagnostic imaging and radionuclide therapy. Eur J Nucl Med Mol Imaging. 2012;39:1876–85.CrossRefPubMed

22.

Virgolini I, Innsbruck Team. Peptide receptor radionuclide therapy (PRRT): clinical significance of re-treatment? Eur J Nucl Med Mol Imaging. 2015;42:1949–54.CrossRefPubMed

23.

Kauhanen S, Seppänen M, Ovaska J, Minn H, Bergman J, Korsoff P, et al. The clinical value of [18F]fluoro-dihydroxyphenylalanine positron emission tomography in primary diagnosis, staging, and restaging of neuroendocrine tumors. Endocr Relat Cancer. 2009;16:255–65.CrossRefPubMed

24.

Fröberg AC, de Jong M, Nock BA, Breeman WA, Erion JL, Maina T, et al. Comparison of three radiolabelled peptide analogues for CCK-2 receptor scintigraphy in medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2009;36:1265–72.CrossRefPubMedPubMedCentral

25.

Gotthardt M, Béhé MP, Beuter D, Battmann A, Bauhofer A, Schurrat T, et al. Improved tumour detection by gastrin receptor scintigraphy in patients with metastasised medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2006;33:1273–9.CrossRefPubMed

26.

Gotthardt M, Béhé MP, Grass J, Bauhofer A, Rinke A, Schipper ML, et al. Added value of gastrin receptor scintigraphy in comparison to somatostatin receptor scintigraphy in patients with carcinoids and other neuroendocrine tumours. Endocr Relat Cancer. 2006;13:1203–11.CrossRefPubMed

27.

Pawlak D, Rangger C, KolencPeitl P, Garnuszek P, Maurin M, Ihli L, et al. From preclinical development to clinical application: kit formulation for radiolabelling the minigastrin analogue CP04 with in-111 for a first-in-human clinical trial. Eur J Pharm Sci. 2016;85:1–9.CrossRefPubMedPubMedCentral

28.

Binderup T, Knigge U, Loft A, Federspiel B, Kjaer A. 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin Cancer Res. 2010;16:978–85.CrossRefPubMed

29.

Woltering EA, Bergsland EK, Beyer DT. Neuroendocrine Tumors of the Stomach. American Joint Committee on Cancer 2017. In: Amin MB editor. AJCC Cancer Staging Manual. Eighth Edition. Springer 2017: 351–359. doi: 10.1007/978-3-319-40618-3_30.

30.

Nilica B, Waitz D, Stevanovic V, Uprimny C, Kendler D, Buxbaum S, et al. Direct comparison of 68Ga-DOTA-TOC and 18F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle. Eur J Nucl Med Mol Imaging. 2016;43:1585–92.CrossRefPubMedPubMedCentral

31.

Ambrosini V, Marzola MC, Rubello D, Fanti S. (68)Ga-somatostatin analogues PET and (18)F-DOPA PET in medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2010;37:46–8.CrossRefPubMed

32.

Conry BG, Papathanasiou ND, Prakash V, Kayani I, Caplin M, Mahmood S, Bomanji JB. Comparison of (68)Ga-DOTATATE and (18)F-fluorodeoxyglucose PET/CT in the detection of recurrent medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2010;37:49–57.CrossRefPubMed

33.

Kayani I, Bomanji JB, Groves A, Conway G, Gacinovic S, Win T, et al. Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG. Cancer. 2008;112:2447–55.CrossRefPubMed

34.

Ambrosini V, Tomassetti P, Castellucci P, Campana D, Montini G, Rubello D, et al. Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2008;35:1431–8.CrossRefPubMed

35.

Fanti S, Ambrosini V, Tomassetti P, Castellucci P, Montini G, Allegri V, et al. Evaluation of unusual neuroendocrine tumours by means of 68Ga-DOTA-NOC PET. Biomed Pharmacother. 2008;62:667–71.CrossRefPubMed

36.

Kayani I, Conry BG, Groves AM, Win T, Dickson J, Caplin M, Bomanji JB. A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors. J Nucl Med. 2009;50:1927–32.CrossRefPubMed

37.

Ambrosini V, Castellucci P, Rubello D, Nanni C, Musto A, Allegri V, et al. 68Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid. Nucl Med Commun. 2009;30:281–6.CrossRefPubMed

38.

Schartinger VH, Dudás J, Decristoforo C, Url C, Schnabl J, Göbel G, et al. ⁶⁸Ga-DOTA⁰-Tyr³-octreotide positron emission tomography in head and neck squamous cell carcinoma. Eur J Nucl Med Mol Imaging. 2013;40:1365–72.CrossRefPubMed

39.

Henze M, Dimitrakopoulou-Strauss A, Milker-Zabel S, Schuhmacher J, Strauss LG, Doll J, et al. Characterization of 68Ga-DOTA-D-Phe1-Tyr3-octreotide kinetics in patients with meningiomas. J Nucl Med. 2005;46:763–9.PubMed

40.

Nanni C, Fantini L, Nicolini S, Fanti S. Non FDG PET. Clin Radiol. 2010;65:536–48.CrossRefPubMed

41.

Chen W. Clinical applications of PET in brain tumors. J Nucl Med. 2007;48:1468–81.CrossRefPubMed

42.

Kauhanen S, Seppänen M, Minn H, Gullichsen R, Salonen A, Alanen K, et al. Fluorine-18-L-dihydroxyphenylalanine (18F-DOPA) positron emission tomography as a tool to localize an insulinoma or beta-cell hyperplasia in adult patients. J Clin Endocrinol Metab. 2007;92:1237–44.CrossRefPubMed

43.

Traub-Weidinger T, Putzer D, von Guggenberg E, Dobrozemsky G, Nilica B, Kendler D, et al. Multiparametric PET imaging in thyroid malignancy characterizing tumour heterogeneity: somatostatin receptors and glucose metabolism. Eur J Nucl Med Mol Imaging. 2015;42:1995–2001.CrossRefPubMed

44.

Prasad V, Ambrosini V, Hommann M, Hoersch D, Fanti S, Baum RP. Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET/CT. Eur J Nucl Med Mol Imaging. 2010;37:67–77.CrossRefPubMed

45.

Putzer D, Gabriel M, Henninger B, Kendler D, Uprimny C, Dobrozemsky G, et al. Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy. J Nucl Med. 2009;50:1214–21.CrossRefPubMed

46.

Ambrosini V, Nanni C, Zompatori M, Campana D, Tomassetti P, Castellucci P, et al. (68)Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2010;37:722–7.CrossRefPubMed

47.

Ugur O, Kothari PJ, Finn RD, Zanzonico P, Ruan S, Guenther I, et al. Ga-66 labeledsomatostatin analogue DOTA-DPhe1-Tyr3-octreotide as a potential agent for positron emission tomography imaging and receptor mediated internal radiotherapy of somatostatin receptor positive tumors. Nucl Med Biol. 2002;29:147–57.CrossRefPubMed

48.

Gabriel M, Oberauer A, Dobrozemsky G, Decristoforo C, Putzer D, Kendler D, et al. 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy. J Nucl Med. 2009;50:1427–34.CrossRefPubMed

49.

Öksüz MÖ, Winter L, Pfannenberg C, Reischl G, Müssig K, Bares R, Dittmann H. Peptide receptor radionuclide therapy of neuroendocrine tumorswith(90)Y-DOTATOC: is treatment response predictable by pre-therapeutic uptake of(68)Ga-DOTATOC? Diagn Interv Imaging. 2014;95:289–300.CrossRefPubMed

50.

Virgolini I, Ambrosini V, Bomanji JB, Baum RP, Fanti S, Gabriel M, et al. Procedureguidelinesfor PET/CT tumourimagingwith 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging. 2010;37:2004–10.

51.

Velikyan I, Sundin A, Eriksson B, Lundqvist H, Sörensen J, Bergström M, Långström B. In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours-impact of peptide mass. Nucl Med Biol. 2010;37:265–75.CrossRefPubMed

52.

Ezziddin S, Lohmar J, Yong-Hing CJ, Sabet A, Ahmadzadehfar H, Kukuk G, et al. Does the pretherapeutictumor SUV in 68Ga DOTATOC PET predict the absorbed dose of 177Lu octreotate? Clin Nucl Med. 2012;37:e141–7.CrossRefPubMed

53.

Machado JS, Beykan S, Herrmann K, Lassmann M. Recommendedadministeredactivitiesfor (68)Ga-labelled peptides in paediatricnuclearmedicine. Eur J Nucl Med Mol Imaging. 2016;43:2036–9.CrossRefPubMed

54.

Hartmann H, Zöphel K, Freudenberg R, Oehme L, Andreeff M, Wunderlich G, et al. Radiation exposure of patients during 68Ga-DOTATOC PET/CT examinations. Nuklearmedizin. 2009;48:201–7.PubMed

55.

Pettinato C, Sarnelli A, Di Donna M, Civollani S, Nanni C, Montini G, et al. 68Ga-DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2008;35:72–9.CrossRefPubMed

56.

Walker RC, Smith GT, Liu E, Moore B, Clanton J, Stabin M. Measured human dosimetry of 68Ga-DOTATATE. J Nucl Med. 2013;54:855–60.CrossRefPubMedPubMedCentral

57.

Koopmans KP, Groot JW, Plukker JT, de Vries EG, Kema IP, Sluiter WJ, et al. 18F-dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: relation to tumor differentiation. J Nucl Med. 2008;49:524–31.CrossRefPubMed

58.

Eriksson B, Orlefors H, Oberg K, Sundin A, Bergström M, Långström B. Developments in PET for the detection of endocrine tumours. Best Pract Res Clin Endocrinol Metab. 2005;19:311–24.CrossRefPubMed

59.

Timmers HJ, Hadi M, Carrasquillo JA, Chen CC, Martiniova L, Whatley M, et al. The effects of carbidopa on uptake of 6-18F-Fluoro-L-DOPA in PET of pheochromocytoma and extraadrenal abdominal paraganglioma. J Nucl Med. 2007;48:1599–606.CrossRefPubMed

60.

Ribeiro MJ, De Lonlay P, Delzescaux T, Boddaert N, Jaubert F, Bourgeois S, et al. Characterization of hyperinsulinism in infancy assessed with PET and 18F-fluoro-L-DOPA. J Nucl Med. 2005;46:560–6.PubMed

61.

Kauhanen S, Seppänen M, Nuutila P. Premedication with carbidopa masks positive finding of insulinoma and beta-cell hyperplasia in [(18)F]-dihydroxy-phenyl-alanine positron emission tomography. J Clin Oncol. 2008;26:5307–8. author reply 5308–9 CrossRefPubMed

62.

Imperiale A, Bahougne T, Goichot B, Bachellier P, Taïeb D, Namer IJ. Dynamic 18F-FDOPA PET findings after carbidopa premedication in 2 adult patients with insulinoma-related hyperinsulinemichypoglycemia. Clin Nucl Med. 2015;40:682–4.CrossRefPubMed

63.

Imperiale A, Sebag F, Vix M, Castinetti F, Kessler L, Moreau F, et al. 18F-FDOPA PET/CT imaging of insulinoma revisited. Eur J Nucl Med Mol Imaging. 2015;42:409–18.CrossRefPubMed

64.

Koopmans KP, Brouwers AH, De Hooge MN, Van der Horst-Schrivers AN, Kema IP, Wolffenbuttel BH, et al. Carcinoid crisis after injection of 6-18F-fluorodihydroxyphenylalanine in a patient with metastatic carcinoid. J Nucl Med. 2005;46:1240–3.PubMed

65.

Nataf V, Balard M, de Beco V, Kerrou K, Gutman F, Grahek D, et al. Safety of 18F-DOPA injection for PET of carcinoid tumor. J Nucl Med. 2006;47:1732. author reply 1732 PubMed

66.

Virgolini I, Gabriel M, Kroiss A, von Guggenberg E, Prommegger R, Warwitz B, et al. Current knowledge on the sensitivity of the(68)Ga-Somatostatinreceptor positron emission tomography and the SUVmaxreference range for management of pancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2016;43:2072–83.CrossRefPubMedPubMedCentral

67.

Kabasakal L, Demirci E, Ocak M, Decristoforo C, Araman A, Ozsoy Y, et al. Comparison of 68Ga-DOTATATE and 68Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2012;39:1271–7.CrossRefPubMed

68.

Wild D, Bomanji JB, Benkert P, Maecke H, Ell PJ, Reubi JC, Caplin ME. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors. J Nucl Med. 2013;54:364–72.CrossRefPubMed

69.

Grassetto G, Massaro A, Cittadin S, Padoan A, Manara R, D’Avella D, et al. Kinetic of 18F-DOPA in basal ganglia of non-human primate. Eur J Nucl Med Mol Imaging. 2009;(Suppl 2):36, S469–S469.

70.

Lopci E, D’Ambrosio D, Nanni C, Chiti A, Pession A, Marengo M, Fanti S. Feasibility of carbidopa premedication in pediatricpatients:a pilot study. Cancer Biother Radiopharm. 2012;27:729–33.CrossRefPubMed

71.

Decristoforo C, Pickett RD, Verbruggen A. Feasibility and availability of ⁶⁸Ga-labelled peptides. Eur J Nucl Med Mol Imaging. 2012;39(Suppl 1):S31–40.CrossRefPubMed

72.

Velikyan I. 68Ga-based radiopharmaceuticals: production and application relationship. Molecules. 2015;20:12913–43.CrossRefPubMed

73.

Balan KK. Visualization of the gall bladder on F-18 FDOPA PET imaging: a potential pitfall. Clin Nucl Med. 2005;30:23–4.CrossRefPubMed

74.

Tessonnier L, Sebag F, Ghander C, De Micco C, Reynaud R, Palazzo FF, et al. Limited value of 18F-F-DOPA PET to localize pancreatic insulin-secreting tumors in adults with hyperinsulinemichypoglycemia. J Clin Endocrinol Metab. 2010;95:303–7.CrossRefPubMed

75.

Koopmans KP, de Vries EG, Kema IP, Elsinga PH, Sluiter WJ, Vanghillewe K, et al. Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study. Lancet Oncol. 2006;7:728–34.CrossRefPubMed

76.

Treglia G, Rufini V, Salvatori M, Giordano A, Giovanella L. PET imaging in recurrent medullary thyroid carcinoma. Int J Mol Imaging. 2012;2012:324686.PubMedPubMedCentral

77.

Treglia G, Cocciolillo F, de Waure C, Di Nardo F, Gualano MR, Castaldi P, et al. Diagnostic performance of 18F-dihydroxyphenylalanine positron emission tomography in patients with paraganglioma: a meta-analysis. Eur J Nucl Med Mol Imaging. 2012;39:1144–53.CrossRefPubMed

78.

Blake MA, Singh A, Setty BN, Slattery J, Kalra M, Maher MM, et al. Pearls and pitfalls in interpretation of abdominal and pelvic PET-CT. Radiographics. 2006;26:1335–53.CrossRefPubMed

Titel: Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F–DOPA
verfasst von: Murat Fani Bozkurt
Irene Virgolini
Sona Balogova
Mohsen Beheshti
Domenico Rubello
Clemens Decristoforo
Valentina Ambrosini
Andreas Kjaer
Roberto Delgado-Bolton
Jolanta Kunikowska
Wim J. G. Oyen
Arturo Chiti
Francesco Giammarile
Stefano Fanti
Publikationsdatum: 25.05.2017
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 9/2017
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-017-3728-y

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Guideline for PET/CT imaging of neuroendocrine neoplasms with ⁶⁸Ga-DOTA-conjugated somatostatin receptor targeting peptides and ¹⁸F–DOPA

Abstract

Purpose & Methods

Results & Conclusion

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose & Methods

Results & Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2017

18F–FDG-PET/CT for systemic staging of patients with newly diagnosed ER-positive and HER2-positive breast cancer

FDG-PET/CT for systemic staging of patients with newly diagnosed breast cancer

18F-fluorodeoxyglucose positron emission tomography in the diagnosis of malignancy in patients with paraneoplastic neurological syndrome: a systematic review and meta-analysis

Diagnosis of recurrent prostate cancer with PET/CT imaging using the gastrin-releasing peptide receptor antagonist 68Ga-RM2: Preliminary results in patients with negative or inconclusive [18F]Fluoroethylcholine-PET/CT

Sentinel lymph node mapping using SPECT/CT and gamma probe in endometrial cancer: an analysis of parameters affecting detection rate

Fibrous dysplasia mimicking bone metastasis on 68GA-PSMA PET/MRI